First Gynecological Procedures Performed with Medtronic Hugo™ Robotic-Assisted Surgery System


2021-07-30 10:00:07 BioSpace


DUBLIN, July 29, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first gynecological (GYN) procedures with the Hugo™ robotic-assisted surgery (RAS) system. The six cases included hysterectomies and myomectomies performed by Salomón Zebede, M.D., and Juan Carlos López, M.D., last week at Pacifica Salud Hospital in Panama City, Panama. "As the cornerstone of our new robotic surgery program, the Hugo RAS system is playing a critical role in bringing the benefits of minimally invasive surgery to more patients in our region," said Dr. Zebede. "It was energizing to perform the very first GYN procedure with the Hugo system, and encouraging to experience firsthand the possibility this technology brings to women's health." Globally, more than 60% of hysterectomies are performed as open procedures,1 even though minimally invasive surgery offers fewer complications, shorter hospital stays, and faster return to normal activities.2-4 Pacifica Salud is the latest institution to join Medtronic's Partners in Possibility Program, a group of pioneering hospitals that will be among the first in the world to use the Hugo RAS system. Earlier this month, the hospital announced its first five urological cases with the Hugo RAS system. Pacifica Salud is also an early adopter of Touch Surgery™ Enterprise, a cloud-based surgical video capture solution that allows surgeons to seamlessly record, analyze, and share surgical video. "We are witnessing the dawn of a new era in robotic surgery," said Mr. Rafael Cohen, CEO of Pacifica Salud. "That is made possible by the Hugo system, our partnership with Medtronic, and our talented team at Pacifica Salud." The Hugo RAS system — Medtronic's solution to historic cost and utilization barriers that have kept surgical robotics out of reach for many hospitals — is a modular, multi-quadrant platform designed for a broad range of soft-tissue procedures. In June, Medtronic announced the first clinical procedures with the Hugo system took place in Santiago, Chile. That marked the beginning of the Hugo RAS system patient registry, which is collecting clinical data to support regulatory submissions around the world. "As an OB/GYN, I'm incredibly passionate about advancing women's health and wellbeing through less invasive solutions that improve outcomes and enable a better quality of life," said Carla Peron, M.D., chief medical officer of the Surgical Robotics business, which is part of Medical Surgical Portfolio at Medtronic. "The first GYN procedures with the Hugo RAS system represent an exciting step toward expanding access to more treatment options, including the benefits of robotic-assisted surgery, to women everywhere." Medtronic has a longstanding history of making a positive impact on women's health through technology. The Hugo RAS system joins a portfolio of gynecological products designed to enable less invasive surgical treatment of a range of conditions including abnormal uterine bleeding, uterine fibroids, and endometrial cancer. "I'm proud of the work we're doing at Medtronic with our healthcare partners around the world to improve women's health," said Megan Rosengarten, president of Surgical Robotics. "Advancing access for women to minimally invasive surgical care is a great responsibility and privilege, which makes today's announcement about the Hugo system all the more meaningful." The Hugo RAS system is not cleared or approved in the U.S. or Europe. Regulatory requirements of individual countries and regions will determine availability and approval or clearance timelines. Touch Surgery Enterprise is available in the U.S. and Europe; it is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition. For more information, visit About Medtronic Medtronic plc (, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. Based on internal estimates and Medtronic report, FY20 market model: procedural volume data. Fitch K, Engel T, Bochner A. Cost differences between open and minimally invasive surgery. Managed Care. 2015 Sep;24(9):40–8. Tiwari MM, Reynoso JF, High R, Tsang AW, Oleynikov D. Safety, efficacy, and cost effectiveness of common laparoscopic procedures. Surg Endosc. 2011;25(4):1127-1135. Roumm AR, Pizzi L, Goldfarb NI, Cohn H. Minimally invasive: minimally reimbursed? An examination of six laparoscopic surgical procedures. Surg Innovation. 2005;12(3):261–287. Contacts: Gary Jeanfaivre Ryan Weispfenning Public Relations Investor Relations +1-203-833-2104 +1-763-505-4626     View original content to download multimedia: SOURCE Medtronic plc
DUBLIN 2021年7月29日电/PRNewswire/--全球医疗技术领导者美敦力(NYSE:MDT)今天宣布首次使用雨果·™机器人辅助手术(RAS)系统进行妇科手术。这六例病例包括上周在巴拿马巴拿马城Pacifica Salud医院由Salomón Zebede医学博士和Juan Carlos López医学博士进行的子宫切除和肌瘤切除。 Zebede博士说:“作为我们新机器人手术项目的基石,Hugo RAS系统在为我们地区的更多患者带来微创手术的好处方面发挥了关键作用。”“用雨果系统进行第一次妇科手术令人兴奋,并鼓励亲身体验这项技术给女性健康带来的可能性。” 在全球范围内,超过60%的子宫切除术是开放式手术,1尽管微创手术并发症少,住院时间短,恢复正常活动更快。2-4 Pacifica Salud是最新加入美敦力可能性合作伙伴计划的机构,该计划是一组开创性的医院,将是世界上首批使用雨果RAS系统的医院之一。本月早些时候,该医院宣布了雨果RAS系统的首批五例泌尿外科病例。Pacifica Salud也是Touch Surgeration™企业的早期采用者,这是一种基于云的手术视频采集解决方案,允许外科医生无缝记录、分析和共享手术视频。 Pacifica Salud首席执行官拉斐尔·科恩先生说:“我们正在见证机器人手术新时代的到来。”“雨果系统、我们与美敦力的合作伙伴关系以及我们在Pacifica Salud的天才团队使这一切成为可能。” 雨果RAS系统是美敦力解决历史成本和使用障碍的解决方案,这些障碍使许多医院无法使用外科机器人,它是一个模块化、多象限平台,为广泛的软组织手术设计。今年6月,美敦力宣布雨果系统的首次临床操作在智利圣地亚哥进行。这标志着雨果RAS系统患者注册表的开始,该系统正在收集临床数据,以支持世界各地的监管提交。 “作为一名妇产科医生,我非常热衷于通过减少侵入性的解决方案来促进妇女的健康和福祉,这些解决方案可以改善结果,提高生活质量,”外科机器人业务的首席医疗官卡拉·庇隆医学博士说,该业务是美敦力医疗外科产品组合的一部分。“Hugo RAS系统的首次妇科手术代表着向世界各地的妇女扩大获得更多治疗选择的机会迈出了令人兴奋的一步,包括机器人辅助手术的好处。” 美敦力在通过技术对女性健康产生积极影响方面有着悠久的历史。雨果RAS系统加入了一系列妇科产品,旨在使包括异常子宫出血、子宫肌瘤和子宫内膜癌在内的一系列疾病的微创手术治疗成为可能。 外科机器人总裁梅根·罗森加滕(Megan Rosengarten)表示:“我为我们在美敦力与世界各地的医疗保健合作伙伴为改善女性健康所做的工作感到自豪。”“促进女性获得微创外科护理是一项巨大的责任和特权,这使得今天关于雨果系统的宣布更加有意义。” 雨果RAS系统在美国或欧洲没有被清除或批准。个别国家和地区的监管要求将决定可用性和批准或清除时间表。触摸手术企业在美国和欧洲均有提供;它不是为了指导手术,或帮助疾病或条件的诊断或治疗。 欲了解更多信息,请访问。 关于美敦力 美敦力公司(总部位于爱尔兰都柏林,是全球最大的医疗技术、服务和解决方案公司之一,为全球数百万人减轻痛苦、恢复健康和延长寿命。美敦力在全球拥有90,000多名员工,为150多个国家的医生、医院和病人提供服务。该公司致力于与世界各地的利益相关者合作,共同推进医疗保健的进一步发展。 任何前瞻性陈述都受到风险和不确定性的影响,如美敦力提交给证券交易委员会的定期报告中描述的风险和不确定性。实际结果可能与预期结果有重大差异。 基于内部估计和美敦力报告,20财年市场模型:程序性批量数据。 Fitch K,Engel T,Bochner A.开放和微创手术的费用差异。管理式护理。2015年9月24日(9):40-8。 Tiwari MM,Reynoso JF,High R,Tsang AW,Oleynikov D.普通腹腔镜手术的安全性、有效性和成本效益。外科内窥镜。2011年;25(4):1127-1135。 Roumm AR,Pizzi L,Goldfarb NI,Cohn H.微创:最低报销?六种腹腔镜手术方法的检查。外科创新。2005年;12(3):261-287。 联系人: 加里·让费弗尔 莱恩·韦斯普芬宁 公共关系 投资者关系 +1-203-833-2104 +1-763-505-4626 查看原始内容下载多媒体: 源|美敦力plc